DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1

Justin W. Leung,Kyle M. Miller
DOI: https://doi.org/10.1016/j.tips.2024.09.008
IF: 17.638
2024-11-08
Trends in Pharmacological Sciences
Abstract:Breast Cancer Type 1 Susceptibility Protein (BRCA)-1 existing in several functionally distinct complexes, promotes DNA repair of DNA double-strand breaks (DSBs). A recent study by Tang and colleagues identifies the lysine methyltransferase Disruptor of Telomeric Silencing 1-Like (DOT1L) involved in modifying Receptor-Associated Protein 80 (RAP80) to promote BRCA1-A complex localization and repair functions at DNA breaks. This study illuminates a potential therapeutic target for cancer radiotherapy.
pharmacology & pharmacy
What problem does this paper attempt to address?